Sofdra® safety and benefit-risk profile reaffirmed in major American dermatology journal
JMM
An article appearing in The Journal of the American Academy of Dermatology (JAAD) reports a favourable risk-benefit profile of Sofdra®
Peer-reviewed brief report analysed spontaneously reported adverse events for Sofdra in the US from 18 June 2024 to 31 January 2026
Confidence in product performance reaffirmed, with postmarketing adverse event types found to be generally consistent with sofpironium’s known safety profile
PHOENIX USA, 17 November 2026: Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), announces that a peer reviewed article analysing US postmarketing safety data for sofpironium topical gel, 12.45%, the drug product branded as Sofdra® in the US, has been published online in the Journal of the American Academy of Dermatology (JAAD).
JAAD, the official scientific publication of the American Academy of Dermatology (AAD), aims to satisfy the educational needs of the dermatology community.
Sofdra is a prescription anticholinergic medicine used on the skin (topical) to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.
During the postmarketing period, 20,667 Sofdra prescriptions were filled, and a total of 194 reports involving 431 adverse events were received from US healthcare providers and consumers. Of these events, 249 were considered drug-related. The authors identified no unexpected adverse events. Adverse event types were consistent with the US prescribing information and the pivotal phase 3 studies. Sixteen serious drug-related adverse event reports, encompassing 29 events, were received in the postmarketing period (0.08% of the postmarketing population). The article was co-authored and supported by Botanix.
No drug-related serious adverse events were observed in the pivotal phase 3 trials.
Botanix Chief Executive Officer Dr Howie McKibbon says, ‘We welcome the publication of this analysis of more than 18 months of US postmarketing experience with Sofdra in JAAD. Transparent reporting of real-world safety data matters to prescribers and patients. We are encouraged that the authors found adverse event types to be generally consistent with the known safety profile of Sofdra.’
Publication details
Green LJ, Hebert AA, Bhatia N, Martin L, Cartwright MM. Postmarketing safety surveillance of sofpironium gel, 12.45%: A novel treatment for primary axillary hyperhidrosis in patients ≥9 years. J Am Acad Dermatol. 2026 Aug 31:S0190-9622(26)03445-6. doi: 10.1016/j.jaad.2026.08.100. Epub ahead of print. PMID: 42674074. The article can be accessed here.
Background
Sofdra is indicated in the US for the treatment of primary axillary hyperhidrosis in patients aged 9 years and older. Two phase 3 trials demonstrated efficacy and safety. The most frequent adverse events in those trials were local application site reactions and mild to moderate transient events consistent with muscarinic 3 receptor inhibition, such as dry mouth, blurred vision, urinary retention and mydriasis.
Postmarketing surveillance is used to evaluate longer-term safety and may identify safety signals not seen in clinical trials. The authors compared spontaneously reported adverse events from the Botanix Global Safety database and the six Periodic Adverse Drug Experience Reports (PADERs) submitted to the US Food and Drug Administration (FDA) with adverse events from the pivotal phase 3 trials. They analysed the data descriptively by system organ class and preferred term.
All Sofdra prescriptions are processed through a single pharmacy network, which allows prescriptions to be tracked by de-identified patient number. The authors report that 61.8% (n=12,792) of patients received product beyond 42 days, the treatment duration in the phase 3 trials.
About us:
Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Phoenix (US), which has received FDA approval for Sofdra, its product for the treatment of primary axillary hyperhidrosis. Sofdra is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.
To learn more, please visit: www.botanixpharma.com
Contact details:
|
Investor and Media Relations |